FMP
GeneThera, Inc.
GTHR
PNK
Inactive Equity
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado.
0.000001 USD
0.0005 (50000%)
DuPont Analysis
The DuPont analysis, pioneered by the DuPont Corporation, offers a structured approach to assessing fundamental performance. It involves breaking down the return on equity (ROE) into various components, aiding investors in comprehending the factors influencing a company's returns.
ROE = Net Income / Average Total Equity
ROE = (Net Income / Sales) * (Revenue / Average Total Assets) * (Average Total Assets / Average Total Equity)
The company's tax burden is (Net income ÷ Pretax profit). This is the proportion of the company's profits retained after paying income taxes. [NI/EBT] The company's interest burden is (Pretax income ÷ EBIT). This will be 1.00 for a firm with no debt or financial leverage. [EBT/EBIT] The company's operating income margin or return on sales (ROS) is (EBIT ÷ Revenue). This is the operating income per dollar of sales. [EBIT/Revenue] The company's asset turnover (ATO) is (Revenue ÷ Average Total Assets). The company's equity multiplier is (Average Total Assets ÷ Average Total Equity). This is a measure of financial leverage. Profitability (measured by profit margin) Asset efficiency (measured by asset turnover) Financial leverage (measured by equity multiplier)
